Narcolepsy;Narkolepsie

Nervenarzt

Volumn 85, Issue 1, 2014, Pages 26-34

  Mayer, G ^a  

^a Klinik für Neurologie   (Germany)

Author keywords

Cataplexy; HLA; Hypocretin; Immunomodulating therapy; Narcolepsy

Indexed keywords

OREXIN;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRAIN NERVE CELL; CATAPLEXY; CEREBROSPINAL FLUID; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HUMAN; HYPNAGOGIC HALLUCINATION; HYPOTHALAMUS; IMMUNOMODULATION; NARCOLEPSY; NEUROIMAGING; PARASOMNIA; PATHOGENESIS; REM SLEEP; SLEEP MEDICINE; SLEEP WAKING CYCLE;

DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; NARCOLEPSY; POLYSOMNOGRAPHY;

EID: 84898542167     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-013-3889-2     Document Type: Article

References (37)

1. American Academy of Sleep Medicine (1994) Practice parameters for the use of stimulants in the treatment of narcolepsy. Standards of Practice Committee of the American Sleep Disorders Association. Sleep 17:348-351
2. American Academy of Sleep Medicine (2005) The international classification of sleep disorders: diagnostic and coding manual, 2. Aufl. American Academy of Sleep Medicine, Westchester
3. Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L et al (2006) EFNS guidelines on management of narcolepsy. Eur J Neurol 13:1035-1048
4. Chen W, Black J, Call P, Mignot E (2005) Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 58:489-490
5. Cvetkovic-Lopes V, Bayer L, Dorsaz S et al (2010) Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 120: 713-719
6. Dauvilliers Y, Abril B, Mas E et al (2009) Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 73(16):1333-1334
7. Dauvilliers Y, Arnulf I, Mignot E (2007) Narcolepsy with cataplexy. Lancet 369:499-511
8. Dauvilliers Y, Delallée N, Jaussent I et al (2012) Normal cerebrospinal fluid histamine and tele-methyl-histamine levels in hypersomnia conditions. Sleep 35:1359-1366. (Dauvilliers, Histamine Metabolites)
9. Dauvilliers Y, Jaussent I, Krams B, Scholz S et al (2012) Non-Dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 7(6):e38977
10. Dodel R, Peter H, Spottke A et al (2007) Health-related quality of life in patients with narcolepsy. Sleep Med 8:733-741
11. Donjacour CE, Lammers GJ (2012) A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res 21(4):479-480
12. Droogleever Fortuyn HA, Swinkels S, Buitelaar J et al (2008) High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep 31(3):335
13. Ebben MR, Krieger AC (2012) Narcolepsy with cataplexy masked by the use of nicotine. J Clin Sleep Med 8(2):195-196
14. Ghei M (2008) Case 36-2007: a woman with rash, fever, and hypotension. N Engl J Med 358 (13):1405
15. Hor H, Kutalik Z, Dauvilliers Y et al (2010) Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 42:786-789
16. Husain AM, Yancy WS Jr, Carwile ST et al (2004) Diet therapy for narcolepsy. Neurology 62(12):2300-2302
17. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A et al (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 35(2):55-60
18. Izzi F, Placidi F, Marciani MG (2009) Effective treatment of narcolepsy-cataplexy with duloxetine. A report of 3 cases. Sleep Med 10:153-154
19. Lin JS, Dauvilliers Y, Arnulf I et al (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 30(1):74-83
20. Luca G, Haba-Rubio J, Dauvilliers Y, Lammers GJ et al (2012) Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res 1-15
21. Maurovich-Horvat E, Kemlink D, Högl B, Frauscher B et al (2013) Narcolepsy and pregnancy: a retrospective evaluation of 249 pregnancies. J Sleep Res. doi:10.1111/jsr.12047
22. Mayer G (2006) Narkolepsie Taschenatlas spezial. Thieme, Stuttgart
23. Mayer G, Kesper K, Ploch T et al (2002) The implications of gender and age at onset of first symptoms in narcoleptic patients in Germany - results from retrospective evaluation of hospital records. Somnologie 6(1):13-18
24. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7(3):e33723
25. Poli F, Overeem S, Lammers G et al (2013) Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 31:994-1007
26. Poli F, Plazzi G, Di Dalmazi G et al (2010) Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 11(4):423-425
27. Rieger M, Mayer G, Gauggel S (2003) Attention deficits in patients with narcolepsy. Sleep 26: 31-35
28. Schuld A, Hebebrand J, Geller F, Pollmächer T (2000) Increased body-mass index in patients with narcolepsy. Lancet 355:1274-1275
29. Serra L, Montagna P, Mignot E et al (2008) Cataplexy features in childhood narcolepsy. Mov Disord 23(6):858-868
30. Tafti M, Hor H, Dauvilliers Y et al (2013) GWAS replication: DQB1 alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep (submitted)
31. Thannickal TC, Moore RY, Nienhuis R et al (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469-474
32. Thannickal TC, Nienhuis R, Siegel JM (2009) Localized loss of hypocretin cells in narcolepsy without cataplexy. 32(8):993-998
33. Thorpy M, Zhao CG, Dauvilliers Y (2013) Management of narcolepsy during pregnancy. Sleep Med 14(4):367-376
34. Wise MS, Arand DL, Auger RR, Brooks SN et al (2007) Treatment of narcolepsy and other hypersomnias of central origin. Sleep 30(12):1712-1727
35. Wu H, Xia FZ, Xu H, Zhai HL et al (2012) Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals. Neuropeptides 46(3):113-118
36. Mignot E, Lammers GJ, Ripley B et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553-1563
37. Menzler K, Belke M, Unger MM et al (2012) DTI reveals hypothalamic and brainstem white matter lesions in patients with idiopathic narcolepsy. Sleep Med 13(6):736-742